Skip to main content
    P

    Pulse Biosciences Inc (PLSE)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $46.36
    -4.08 (-8.09%)

    Market Cap: $3.71B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Pulse Biosciences Inc (PLSE) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Pulse Biosciences (PLSE) is expected to report earnings on Feb 17, 2027. In the quarter ended Sep 30, 2026, Pulse Biosciences reported EPS of -$0.32, above the -$0.35 estimate. It beat the EPS estimate in 4 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    42%(13/31)
    Avg Surprise
    -2.43%
    Streak
    1 Q

    Upcoming Estimates

    Reports Feb 17, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.37
    Range-$0.38 - -$0.37
    8 analysts
    Revenue Consensus
    $632.40K
    Range$392.00K - $840.00K
    8 analysts
    Reports May 3, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.29
    Range-$0.31 - -$0.27
    2 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.32+9.4%
    60d ago-$0.32+9.4%
    30d ago-$0.31+4.9%
    7d ago-$0.31+4.9%
    Current-$0.29
    Revenue Consensus
    $743.33K
    Range$400.00K - $1.00M
    3 analysts

    Next Report

    PLSE has an expected report date of Feb 17, 2027.

    PLSE Earnings Call

    The latest PLSE earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 31 quarters below that had an estimate, PLSE beat 13, missed 17 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $395000, up 359.3% from $86000 a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.32-$0.35N/A+8.57%BeatN/A40 up, 1 downNov 5, 2026$395000
    Jun 30, 2026-$0.36-$0.31-$0.33 - -$0.24-16.13%MissN/A20 up, 1 downAug 6, 2026$434000
    Mar 31, 2026-$0.24-$0.22-$0.22 - -$0.22-9.73%MissN/A10 up, 0 downMay 4, 2026$401000
    Dec 31, 2025-$0.18-$0.21N/A+14.29%BeatN/A11 up, 0 downFeb 19, 2026$264000
    Sep 30, 2025-$0.29-$0.31-$0.31 - -$0.31+6.45%BeatN/A10 up, 0 downNov 5, 2025$86000
    Jun 30, 2025-$0.28-$0.26N/A-7.69%MissN/AN/A0 up, 0 downAug 12, 2025N/A
    Mar 31, 2025-$0.25N/AN/AN/AN/AN/AN/AN/AMay 8, 2025N/A
    Dec 31, 2024-$0.31-$0.24N/A-30.17%MissN/AN/AN/AMar 27, 2025$1.66M
    Sep 30, 2024-$0.21-$0.24N/A+13.50%BeatN/AN/AN/AOct 30, 2024N/A
    Jun 30, 2024-$0.20-$0.20N/A+0.45%BeatN/AN/AN/AAug 12, 2024N/A
    Mar 31, 2024-$0.18-$0.24N/A+25.00%BeatN/AN/AN/AMay 7, 2024N/A
    Dec 31, 2023-$0.22-$0.24N/A+9.71%BeatN/AN/A0 up, 0 downMar 28, 2024$1.74M
    Sep 30, 2023-$0.19-$0.22N/A+13.64%BeatN/AN/A0 up, 0 downNov 13, 2023N/A
    Jun 30, 2023-$0.22-$0.24N/A+8.33%BeatN/A10 up, 0 downAug 10, 2023N/A
    Mar 31, 2023-$0.26-$0.22-$0.22 - -$0.22-18.18%MissN/A10 up, 0 downMay 11, 2023N/A
    Dec 31, 2022-$0.25-$0.24-$0.24 - -$0.24-4.17%MissN/A10 up, 0 downMar 30, 2023N/A
    Sep 30, 2022-$0.49-$0.45-$0.45 - -$0.45-8.89%MissN/A10 up, 0 downNov 10, 2022N/A
    Jun 30, 2022-$0.44-$0.40-$0.42 - -$0.37-10.00%MissN/A30 up, 0 downAug 10, 2022$265000
    Mar 31, 2022-$0.58-$0.52-$0.56 - -$0.50-11.54%MissN/A30 up, 0 downMay 11, 2022$444000
    Dec 31, 2021-$0.52-$0.51-$0.54 - -$0.49-1.96%MissN/A30 up, 0 downMar 31, 2022$844000
    Sep 30, 2021-$0.48-$0.53-$0.54 - -$0.53+9.43%BeatN/A3N/ANov 15, 2021$574000
    Jun 30, 2021-$0.48-$0.52N/A+7.69%BeatN/A3N/AAug 9, 2021N/A
    Mar 31, 2021-$0.44-$0.49-$0.52 - -$0.47+10.20%BeatN/A2N/AMay 10, 2021N/A
    Dec 31, 2020-$0.54-$0.45-$0.45 - -$0.45-20.00%MissN/A1N/AFeb 22, 2021N/A
    Sep 30, 2020-$0.51-$0.44-$0.44 - -$0.44-15.91%MissN/A1N/ANov 9, 2020N/A
    Jun 30, 2020-$0.53-$0.50-$0.50 - -$0.50-6.00%MissN/A1N/AAug 10, 2020N/A
    Mar 31, 2020-$0.57-$0.47-$0.47 - -$0.47-21.28%MissN/A1N/AMay 11, 2020$78000
    Dec 31, 2019-$0.66-$0.61-$0.61 - -$0.61-8.20%MissN/A1N/AMar 16, 2020N/A
    Sep 30, 2019-$0.57-$0.61-$0.61 - -$0.61+6.56%BeatN/A1N/ANov 7, 2019$218000
    Jun 30, 2019-$0.55-$0.51-$0.51 - -$0.51-7.84%MissN/A1N/AAug 8, 2019$290000
    Mar 31, 2019-$0.49-$0.44-$0.44 - -$0.44-11.36%MissN/A1N/AApr 30, 2019$332000
    Dec 31, 2018-$0.51-$0.51N/A0.00%In lineN/AN/AN/AMar 14, 2019$135000
    Sep 30, 2018-$0.64N/AN/AN/AN/AN/AN/AN/AOct 30, 2018$118000
    Jun 30, 2018-$0.54N/AN/AN/AN/AN/AN/AN/AJul 31, 2018$137000
    Mar 31, 2018-$0.51N/AN/AN/AN/AN/AN/AN/AMay 8, 2018$56000
    Dec 31, 2017-$0.52N/AN/AN/AN/AN/AN/AN/AMar 16, 2018$128000
    Sep 30, 2017-$0.52N/AN/AN/AN/AN/AN/AN/ANov 7, 2017$39000
    Jun 30, 2017-$0.43N/AN/AN/AN/AN/AN/AN/AJul 27, 2017$41000
    Mar 31, 2017-$0.23N/AN/AN/AN/AN/AN/AN/AMay 4, 2017$39000
    Dec 31, 2016-$0.21N/AN/AN/AN/AN/AN/AN/AMar 14, 2017$34000
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$1.00, after -$0.90 the year before. It was -$0.65 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$1.00N/A
    Dec 31, 2024-$0.90N/A
    Dec 31, 2023-$0.89N/A
    Dec 31, 2022-$1.76N/A
    Dec 31, 2021-$1.92N/A
    Dec 31, 2020-$2.15N/A
    Dec 31, 2019-$2.27N/A
    Dec 31, 2018-$2.20N/A
    Dec 31, 2017-$1.70N/A
    Dec 31, 2016-$0.65N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 9,700 words across 10 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20269,69810
    2026Q2Jun 30, 20268,2019
    2026Q1Mar 31, 20265,6496
    2025Q4Dec 31, 20256,5099
    2025Q3Sep 30, 20253,8615
    2025Q2Jun 30, 20254,5566
    2025Q1Mar 31, 20252,7754
    2024Q4Dec 31, 20243,8774

    2026Q3 Earnings Call

    Opening remarks

    Tripp Taylor Investor Relations Thank you, operator. Before we begin, I'd like to inform you that comments and responses to your questions during today's call reflect management's views as of today, November 5, 2026, only and will include forward-looking statements and opinion statements, including predictions, estimates, plans, expectations, and other similar information. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are more fully described in our press release issued today and in our filings with the U.S. Securities and Exchange Commission. Our SEC filings can be found on our website or on the SEC's website. Investors are cautioned not to place undue reliance on forward-looking statements. We disclaim any obligation to update or revise these forward-looking statements. We will also discuss certain non-GAAP financial measures. Disclosures regarding these non-GAAP financial measures, including reconciliations with the most comparable GAAP measures, can be found in the press release. Please note that this conference call will be available for audio replay on our website at pulsebiosciences.com in the News and Events section on our Investor Relations page. With that, I would now like to turn the call over to Co-Chair of the Board and Chief Executive Officer, Paul LaViolette.

    Paul LaViolette Co-Chair of the Board and CEO Thank you, Tripp. Good afternoon, and thank you, everyone, for joining us today to discuss our third quarter 2026 results and business progress. The team at Pulse Biosciences delivered a strong quarter, and we are looking forward to creating continued momentum in Q4 and into 2027. I will begin by describing the technology at the core of everything we do at Pulse Biosciences: our proprietary Nanosecond Pulse Field Ablation energy, or nsPFA, technology. nsPFA produces a fundamentally unique form of non-thermal ablation energy with a differentiated mechanism of action to treat cells. Because our pulses last only billionths of a second, there is virtually no energy deposition that converts to heat and almost no rise in the temperature of the tissue being treated or of adjacent areas. The unique nsPFA energy acts on the membranes of the structures inside the cell, causing the cell to undergo regulated cell death without unwanted inflammatory responses. In addition, this energy is delivered very efficiently. High-efficiency energy delivery allows our catheter system to produce cardiac ablation lesions in tissue that are larger, deeper, and more consistent than lesions created with early-generation PFA systems. The combination of highly efficient lesion production and a very effective ablation mechanism of action results in a non-thermal ablation with exceptional procedural workflow efficiency, very reliable lesion formation, and minimized risk of collateral tissue injury.

    Frequently Asked Questions About PLSE

    When is Pulse Biosciences's next earnings date?

    Pulse Biosciences's next earnings report is expected for Feb 17, 2027.

    Did PLSE beat earnings estimates last quarter?

    Yes. Pulse Biosciences reported EPS of -$0.32 for the quarter ended Sep 30, 2026, above the -$0.35 estimate, a 8.57% surprise.

    What EPS do analysts expect from PLSE next quarter?

    The consensus EPS estimate for Pulse Biosciences for the quarter ending Dec 31, 2026 is -$0.37 from 8 analysts, with estimates from -$0.38 to -$0.37.

    How often does PLSE beat earnings estimates?

    Pulse Biosciences beat the EPS estimate in 4 of the 8 most recent quarters that had an estimate, with an average surprise of -2.61%.